GoKawiilTempus AI Positioned to Profit as Moderna-Merck Cancer Vaccine Push Advances
As Moderna and Merck develop personalized cancer therapies, data and diagnostics firm Tempus AI is emerging as a key infrastructure player supporting that work. Personalis, a genomic testing company, sits at the center of this positioning, suggesting a broader supply-chain opportunity beyond the drugmakers themselves.